Can we count your visit with Google Analytics? No ads, no profiles. Details
ABBV
USHealth Care · Pharmaceuticals
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Post-Humira-LOE pharma re-up: Skyrizi + Rinvoq combined are tracking to surpass peak Humira revenue ($20B+ run-rate), with management guiding ex-Humira growth >$27B by 2027. Allergan (2020, $63B) added Botox aesthetics + Vraylar cash flow; ImmunoGen (2023, $10B) added Elahere ADC; Cerevel (2024, $8.7B) added emraclidine for schizophrenia (Phase II miss late-2024 reset the bull case).
It reads our $ABBV data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.